Interview with Safia Rizvi, Managing Director, UCB India
You have only recently been appointed Managing Director for the first time in your career. How did your first year with UCB India go so far? My first year at…
Address: 504, Peninsula TowersPeninsula Corporate ParkGanpatrao Kadam Marg, Lower ParelIND – Mumbai 400 013,India
Tel: +91 22 40 49 11 11
Web: http://www.ucb.com/india/
At UCB our sense of purpose is to help people suffering from severe central nervous system or immunological disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by the patients’ needs.
UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8500 talented employees, a strong market presence in more than 40 countries, € 3.2 billion in revenue (2010) and numerous strategic partnerships across the industry.
We combine biology and chemistry to make major breakthroughs.
By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
We partner with the leaders in the pharmaceutical industry.
The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we have teamed up with partners – we play to our strengths and tap into the organisations with greater or complementary strengths.
UCB’s medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Vimpat® (lacosamide)
Epilepsy
Keppra® (levetiracetam)
Epilepsy
Neupro® (rotigotine)
Parkinson’s disease
Restless Legs Syndrome
Nootropil® (piracetam)
Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII)
Attention Deficit Hyperactivity Disorder (ADHD)
Cimzia® (certolizumab pegol)
Crohn’s disease
Rheumatoid arthritis
Xyzal® (levocetirizine)
Allergies
Zyrtec® (cetirizine)
Allergies
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII)
Respiratory disease
You have only recently been appointed Managing Director for the first time in your career. How did your first year with UCB India go so far? My first year at…
Vivek Sharma, CEO of Piramal Pharma Solutions (PPS), one of the world’s leading CDMOs with a presence in North America, Europe, and Asia, provides insights into the main trends shaping…
Swati Jajodia, managing director of Swati Spentose discusses her commitment to tackling underserved diseases and the company’s approach to bringing pentosan polysulfate to global markets while working with Key Opinion…
Jai and Sameer Hiremath of Hikal provide insights into the main trends shaping the Indian and global CDMO industry. They articulate how Hikal’s long-standing focus on quality standards, regulatory compliance,…
Dr. Hemant Koshia, commissioner of the FDCA Gujarat, the regulatory authority of the state of Gujarat – India’s leading hub for the production of pharmaceutical and healthcare products – provides…
Dr. Georges Jabre, the recently appointed CEO of Serdia Pharmaceuticals (India) Pvt. Ltd. (an affiliate of the Servier Group) and president of the Healthcare Committee of the Indo-French Chamber of…
Bharat V. Daftary, chairman and MD of Bharat Serums & Vaccines (BSV), a biopharmaceutical company with R&D units in USA, Germany & India and with a presence in over 76…
Yugal Sikri, chairman of the Pharmaceutical Management Program of the prestigious NMIMS University, and with an extremely rich experience in the pharmaceutical industry, explains his mission to build a valuable…
Raghuveer Kini, executive director of the Pharmaceuticals Export Promotion Council of India (Pharmexcil) provides insights into the key success factors that have allowed India to become the world’s pharmaceutical hub…
Jean-Pierre Baylet, country head for India and cluster head for South Asia at Sanofi Pasteur, provides insights into the progress and room for improvement that lie ahead for India’s immunization…
Dr. Deepak Sawant, Minister of Public Health and Family Welfare in the Government of Maharashtra, provides insights into some crucial achievements with regards to the state’s infant and child mortality…
The global pharmaceutical outsourcing market was estimated to be USD 115.7 billion in 2016, of which 49 percent is accounted for by contract research organisations (CROs). Within India, the contract…
In this exclusive interview, Binish Chudgar, vice-chairman and managing director of Intas, the largest privately-owned Indian pharmaceutical company with sales of over USD 1.7 billion during the last financial year,…
See our Cookie Privacy Policy Here